SCN1A の新しい機能喪失変異は,早期発症の複雑な発作と関連しています.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
PubMedで要約を見る
まとめ
この要約は機械生成です。新しいSCN1A遺伝子変異体であるNa<sub>V</sub>1.1<sup>A333V</sup>は,治療が難しい発作を患った子供で特定されました. 機能的研究により この変異は機能の喪失を引き起こし の診断に役立ちます
科学分野
- 遺伝学
- 神経科学
- 分子生物学
背景
- SCN1A遺伝子変異は,GEFS+とDravet症候群を含むの一般的な原因です.
- 早期発症した発作は,SCN1A関連性の兆候である.
研究 の 目的
- 治療に抵抗性のある早期発症発作の小児における新しいSCN1A変種を特定し,機能的に特徴づけること.
- 特定された変異体がNav1.1チャンネル機能に与える影響を調査する.
主な方法
- 発熱発作を繰り返した 患者の遺伝子解析
- Xenopus laevis卵細胞とHEK293T細胞におけるSCN1A変種 (Na<sub>V</sub>1.1<sup>A333V</sup>) の電気生理学的特徴.
主要な成果
- 新しい SCN1A 変異体,c.998C>T (p.Ala333Val) が確認されました.
- Na<sub>V</sub>1.1<sup>A333V</sup>変種は,活性化と可用性の脱極化シフトを示し,Na+の流入が減少し,機能の喪失を示した.
- この変種はgnomADデータベースに含まれず,以前は臨床データベースに報告されていませんでした.
結論
- 特定されたNa<sub>V</sub>1.1<sup>A333V</sup>変種は,再発する複雑な発作と関連しており,機能喪失のフェノタイプを示している.
- SCN1A変異の機能的特徴は,患者の個別化された診断の洞察を提供します.
- SCN1A変異体の機能を理解すると,エピレプシーの治療戦略が改善される可能性があります.
関連する概念動画
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Focal aware seizures: In these seizures, the person remains conscious...
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...